EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NovoCure's enterprise value is $1,013.5 Mil.
NovoCure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-177.5 Mil. Therefore, NovoCure's EV-to-EBITDA for today is -5.71.
The historical rank and industry rank for NovoCure's EV-to-EBITDA or its related term are showing as below:
NVCR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -31863.79 Med: -17.89 Max: 1872.18
Current: -5.71
During the past 11 years, the highest EV-to-EBITDA of NovoCure was 1872.18. The lowest was -31863.79. And the median was -17.89.
NVCR's EV-to-EBITDA is ranked worse than 100% of 489
companies
in the Medical Devices & Instruments industry
Industry Median: 15.23
vs NVCR: -5.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-26), NovoCure's stock price is $12.23.
NovoCure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.950. Therefore, NovoCure's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
NovoCure EV-to-EBITDA Historical Data
The historical data trend for NovoCure's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NovoCure's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NovoCure's EV-to-EBITDA falls into.
NovoCure EV-to-EBITDA Calculation
NovoCure's EV-to-EBITDA for today is calculated as:
NovoCure's current Enterprise Value is $1,013.5 Mil.
NovoCure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-177.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure (NAS:NVCR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
NovoCure's share price for today is $12.23.
NovoCure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of NovoCure's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVCR has been successfully added to your 